Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 4/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CHRNG | P07510 | 1/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.45 |
| ▸ | CHRND | Q07001 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2631406 | 1.00 | GRIA1 (0.48) | GRIA1FOLH1PTPN1CHRNA1CHRNG | |
| SCHEMBL21881743 | 0.90 | FOLH1 (0.50) | GRIA1FOLH1PTPN1CHRNA1CHRNG | |
| SCHEMBL2631415 | 0.84 | HDAC3 (0.42) | GRIA1PTPN1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL12384334 | 0.84 | HDAC3 (0.42) | GRIA1PTPN1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL2099399 | 0.79 | NPSR1 (0.56) | PTPN1 | |
| SCHEMBL2099396 | 0.79 | NPSR1 (0.56) | PTPN1 | |
| SCHEMBL14761090 | 0.74 | CHRNB2 (0.63) | GRIA1PTPN1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL14761872 | 0.74 | CHRNB2 (0.63) | GRIA1PTPN1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL14761840 | 0.74 | CHRNB2 (0.63) | GRIA1PTPN1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL14761539 | 0.74 | CHRNB2 (0.63) | GRIA1PTPN1CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440988-B2 | Regulators of the hedgehog pathway, compositions and uses related thereto | JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2016-09-13 | — | — | US | disclosed |
| US-20120135066-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | BEACHY PHILIP A (US) | 2012-05-31 | — | — | US | disclosed |
| US-8163719-B2 | Regulators of the hedgehog pathway, compositions and uses related thereto | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110263519-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2011-10-27 | — | — | US | disclosed |
| US-7998946-B2 | Veratrum-type alkaloid inhibits mitotic cell proliferation in hedgehog-mediated signal transduction with an ED50 of 1 mM or less; preparations administered systemically, locally, topically; cancer; non-malignant hyperproliferative disorders | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998946-B2 | Veratrum-type alkaloid inhibits mitotic cell proliferation in hedgehog-mediated signal transduction with an ED50 of 1 mM or less; preparations administered systemically, locally, topically; cancer; non-malignant hyperproliferative disorders | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2011-08-16 | — | — | US | disclosed |
| US-7476661-B2 | Regulators of the hedgehog pathway, compositions and uses related thereto | JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080255059-A1 | Regulators of the hedgehog pathway, compositions and uses related thereto | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255059-A1 | Regulators of the hedgehog pathway, compositions and uses related thereto | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255059-A1 | Regulators of the hedgehog pathway, compositions and uses related thereto | SHH, GLI1, SMO | GRIA1 1921/4885FOLH1 840/4885PTPN1 1986/4885 |
| US-20120135066-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | SHH, GLI1, SMO | GRIA1 1921/4885FOLH1 840/4885PTPN1 1986/4885 |
| US-20110263519-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | SHH, GLI1, SMO | GRIA1 1921/4885FOLH1 840/4885PTPN1 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.